|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.260 USD | -59.35% |
|
-.--% | - |
| 12-16 | Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 | CI |
| 12-02 | Top Midday Decliners | MT |
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | -84.78 | -106.5 | -208.63 | -180.62 | -112.17 | |||
Return on Total Capital | -121.74 | -184.48 | 1.02K | 3.93K | -188.99 | |||
Return On Equity % | -197.66 | -301.42 | 1.36K | 2.09K | -310.85 | |||
Return on Common Equity | -197.66 | -301.42 | 1.36K | 2.09K | -310.85 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | -3.34K | -6.03K | -7.89K | -30.7K | -735.53 | |||
SG&A Margin | 1.85K | 2.45K | 4.82K | 32.92K | 848.88 | |||
EBITDA Margin % | -5.18K | -8.47K | -12.71K | -63.55K | -1.58K | |||
EBITA Margin % | -5.19K | -8.48K | -12.71K | -63.62K | -1.58K | |||
EBIT Margin % | -5.19K | -8.48K | -12.71K | -63.62K | -1.58K | |||
Income From Continuing Operations Margin % | -5.17K | -8.49K | -12.74K | -39.93K | -1.6K | |||
Net Income Margin % | -5.17K | -8.49K | -12.74K | -39.93K | -1.6K | |||
Net Avail. For Common Margin % | -5.17K | -8.49K | -12.74K | -39.93K | -1.6K | |||
Normalized Net Income Margin | -3.24K | -5.31K | -7.96K | -24.96K | -987.07 | |||
Levered Free Cash Flow Margin | -2.71K | -5.18K | -9.9K | -47.96K | -1.57K | |||
Unlevered Free Cash Flow Margin | -2.71K | -5.18K | -9.9K | -47.96K | -1.6K | |||
Asset Turnover | ||||||||
Asset Turnover | 0.03 | 0.02 | 0.03 | 0 | 0.11 | |||
Fixed Assets Turnover | 2.12 | 1.44 | 0.56 | 0.1 | 10.07 | |||
Short Term Liquidity | ||||||||
Current Ratio | 4.3 | 0.66 | 0.86 | 0.66 | 3.5 | |||
Quick Ratio | 4.12 | 0.37 | 0.55 | 0.28 | 1.38 | |||
Operating Cash Flow to Current Liabilities | -3.36 | -3.39 | -3.86 | -2.68 | -3.13 | |||
Average Days Payable Outstanding | 64.06 | 72.63 | 107.42 | 139.88 | 111.96 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | 0.57 | -10.08 | -90.23 | -26.94 | 0.43 | |||
Total Debt / Total Capital | 0.56 | -11.21 | -923.97 | -36.88 | 0.43 | |||
LT Debt/Equity | 0.14 | -8.03 | -57.91 | -9.59 | - | |||
Long-Term Debt / Total Capital | 0.14 | -8.93 | -592.97 | -13.12 | - | |||
Total Liabilities / Total Assets | 23.23 | 143.55 | 104.16 | 117.53 | 27.52 | |||
EBIT / Interest Expense | - | - | - | - | -28.49 | |||
EBITDA / Interest Expense | - | - | - | - | -28.31 | |||
(EBITDA - Capex) / Interest Expense | - | - | - | - | -28.31 | |||
Total Debt / EBITDA | -0.01 | -0.01 | -0.01 | -0.01 | -0 | |||
Net Debt / EBITDA | 1.1 | 0.09 | 0.11 | 0 | 0.32 | |||
Total Debt / (EBITDA - Capex) | -0.01 | -0.01 | -0.01 | -0.01 | -0 | |||
Net Debt / (EBITDA - Capex) | 1.1 | 0.09 | 0.11 | 0 | 0.32 | |||
Growth Over Prior Year | ||||||||
Total Revenues, 1 Yr. Growth % | - | -27.64 | -57.76 | -87.4 | 5.27K | |||
Gross Profit, 1 Yr. Growth % | 63.51 | 30.61 | -44.69 | -50.98 | 28.62 | |||
EBITDA, 1 Yr. Growth % | 44.08 | 18.27 | -36.68 | -36.97 | 33.78 | |||
EBITA, 1 Yr. Growth % | 44.09 | 18.26 | -36.66 | -36.95 | 33.71 | |||
EBIT, 1 Yr. Growth % | 44.09 | 18.26 | -36.66 | -36.95 | 33.71 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | 2.96 | 18.96 | -36.64 | -60.51 | 115.29 | |||
Net Income, 1 Yr. Growth % | 2.96 | 18.96 | -36.64 | -60.51 | 115.29 | |||
Normalized Net Income, 1 Yr. Growth % | 43.99 | 18.37 | -36.64 | -60.51 | 112.35 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | - | - | -87.95 | -92.18 | -65.44 | |||
Net Property, Plant and Equip., 1 Yr. Growth % | -33.43 | 66.13 | -25.02 | -36.61 | -62.01 | |||
Total Assets, 1 Yr. Growth % | 262.68 | -79.89 | -6.87 | -48.96 | 437.15 | |||
Tangible Book Value, 1 Yr. Growth % | 637.1 | -111.4 | -91.1 | 114.95 | -2.32K | |||
Common Equity, 1 Yr. Growth % | 637.1 | -111.4 | -91.1 | 114.95 | -2.32K | |||
Cash From Operations, 1 Yr. Growth % | 44.43 | 22.77 | -23.16 | -59.67 | 49.02 | |||
Capital Expenditures, 1 Yr. Growth % | -95.24 | - | - | - | - | |||
Levered Free Cash Flow, 1 Yr. Growth % | 48.16 | 38.16 | -18.96 | -38.93 | 76.26 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | 48.16 | 38.16 | -18.96 | -38.93 | 78.59 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
Total Revenues, 2 Yr. CAGR % | - | - | -44.72 | -76.93 | 160.11 | |||
Gross Profit, 2 Yr. CAGR % | - | 46.14 | -15.01 | -47.93 | -20.6 | |||
EBITDA, 2 Yr. CAGR % | - | 30.54 | -13.46 | -36.82 | -8.18 | |||
EBITA, 2 Yr. CAGR % | 130.83 | 30.54 | -13.45 | -36.8 | -8.18 | |||
EBIT, 2 Yr. CAGR % | 130.83 | 30.54 | -13.45 | -36.8 | -8.18 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | 126.47 | 10.67 | -13.18 | -49.98 | -7.79 | |||
Net Income, 2 Yr. CAGR % | 126.47 | 10.67 | -13.18 | -49.98 | -7.79 | |||
Normalized Net Income, 2 Yr. CAGR % | 127.04 | 30.55 | -13.4 | -49.98 | -8.42 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | - | -90.29 | -83.56 | |||
Net Property, Plant and Equip., 2 Yr. CAGR % | - | 5.16 | 11.61 | -31.05 | -50.93 | |||
Total Assets, 2 Yr. CAGR % | 2.6K | -14.6 | -56.73 | -31.06 | 65.57 | |||
Tangible Book Value, 2 Yr. CAGR % | 179.69 | -8.31 | -89.92 | -56.26 | 590.92 | |||
Common Equity, 2 Yr. CAGR % | 179.69 | -8.31 | -89.92 | -56.26 | 590.92 | |||
Cash From Operations, 2 Yr. CAGR % | 218.32 | 33.16 | -2.72 | -44.33 | -22.47 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | 484.69 | 43.08 | 5.56 | -29.65 | 3.75 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 496.91 | 43.08 | 5.56 | -29.65 | 4.44 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
Total Revenues, 3 Yr. CAGR % | - | - | - | -66.23 | 41.91 | |||
Gross Profit, 3 Yr. CAGR % | - | - | 5.71 | -29.25 | -29.62 | |||
EBITDA, 3 Yr. CAGR % | - | - | 2.57 | -22.14 | -18.87 | |||
EBITA, 3 Yr. CAGR % | 264.37 | 84.71 | 2.58 | -22.12 | -18.87 | |||
EBIT, 3 Yr. CAGR % | 264.37 | 84.71 | 2.58 | -22.12 | -18.87 | |||
Earnings From Cont. Operations, 3 Yr. CAGR % | 202.76 | 82.73 | -8.1 | -33.23 | -18.63 | |||
Net Income, 3 Yr. CAGR % | 202.76 | 82.73 | -8.1 | -33.23 | -18.63 | |||
Normalized Net Income, 3 Yr. CAGR % | 203.26 | 82.73 | 2.6 | -33.34 | -19 | |||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | - | -85.18 | |||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | -6.05 | -7.57 | -43.48 | |||
Total Assets, 3 Yr. CAGR % | 1.65K | 427.35 | -12.1 | -54.28 | 36.67 | |||
Tangible Book Value, 3 Yr. CAGR % | 110.36 | -3.73 | -57.86 | -72.06 | 61.97 | |||
Common Equity, 3 Yr. CAGR % | 110.36 | -3.73 | -57.86 | -72.06 | 61.97 | |||
Cash From Operations, 3 Yr. CAGR % | 222.55 | 131.71 | 10.98 | -27.46 | -22.7 | |||
Levered Free Cash Flow, 3 Yr. CAGR % | - | 261.48 | 18.19 | -12.04 | -4.45 | |||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | 266.49 | 18.19 | -12.04 | -4.03 | |||
Compound Annual Growth Rate Over Five Years | ||||||||
Gross Profit, 5 Yr. CAGR % | - | - | - | - | -5.73 | |||
EBITDA, 5 Yr. CAGR % | - | - | - | - | -1.87 | |||
EBITA, 5 Yr. CAGR % | - | - | 105.04 | 20.27 | -1.87 | |||
EBIT, 5 Yr. CAGR % | - | - | 105.04 | 20.27 | -1.87 | |||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | 83.7 | 8.83 | -7.98 | |||
Net Income, 5 Yr. CAGR % | - | - | 83.7 | 8.83 | -7.98 | |||
Normalized Net Income, 5 Yr. CAGR % | - | - | 83.7 | 8.83 | -1.96 | |||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | - | -27.54 | |||
Total Assets, 5 Yr. CAGR % | - | - | 298.26 | 133.7 | 13.24 | |||
Tangible Book Value, 5 Yr. CAGR % | - | - | -37.61 | -29.78 | 29 | |||
Common Equity, 5 Yr. CAGR % | - | - | -37.61 | -29.78 | 29 | |||
Cash From Operations, 5 Yr. CAGR % | - | - | 99.69 | 31.06 | -3.86 | |||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 87.65 | 12.19 | |||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 89.21 | 12.48 |
- Stock Market
- Stocks
- SONN Stock
- Financials Sonnet Biotherapeutics
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















